VBLT - VBL Therapeutics expands the ovarian cancer trial in Europe

VBL Therapeutics (VBLT) has announced that it has enrolled the first patient in Europe in the ongoing Phase 3 study for VB-111 for platinum-resistant ovarian cancer.The randomized registration clinical trial comparing a combination of VB-111 and paclitaxel to placebo plus paclitaxel is in progress in the U.S. and Israel, seeking to recruit approximately 400 patients.VB-111 is a first-in-class, targeted anti-cancer gene-therapy agent under clinical development for a wide range of solid tumors. It has received the Orphan Designation from the European Commission for the treatment of ovarian cancer.Based on the interim analysis conducted after enrolling nearly 200 patients, VB-111 has shown a response rate of 58% or higher in the first 60 patients with >50% response rate maintained in the total evaluable patient population.Issuing a corporate update in November, the company CEO, Dror Harats, said at the time, “while it is important to note that the study remains blinded, we are

For further details see:

VBL Therapeutics expands the ovarian cancer trial in Europe